Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases
Pharmaceutics · 19.12.2024 · 16 (12) · 1611
DOI: 10.3390/pharmaceutics16121611 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 19.12.2024. Verfasst von Yimai Jiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology…. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, NSFC, Distinguished Young Scholars Science Fund of the Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
The blood–brain barrier (BBB) serves as a highly selective barrier between the blood and the central nervous system (CNS), and its main function is to protect the brain from foreign substances. This physiological property plays a crucial role in maintaining CNS homeostasis, but at the same time greatly limits the delivery of drug molecules to the CNS, thus posing a major challenge for the treatment of neurological diseases. Given that the high incidence and low cure rate of neurological diseases have become a global public health problem, the development of effective BBB penetration technologies is important for enhancing the efficiency of CNS drug delivery, reducing systemic toxicity, and improving the therapeutic outcomes of neurological diseases. This review describes the physiological and pathological properties of the BBB, as well as the current challenges of trans-BBB drug delivery, detailing the structural basis of the BBB and its role in CNS protection. Secondly, this paper reviews the drug delivery strategies for the BBB in recent years, including physical, biological and chemical approaches, as well as nanoparticle-based delivery technologies, and provides a comprehensive assessment of the effectiveness, advantages and limitations of these delivery strategies. It is hoped that the review in this paper will provide valuable references and inspiration for future researchers in therapeutic studies of neurological diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China.
- School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300401, China.
- Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 3000…
Förderung
- National Key Research and Development Program of China
- NSFC
- Distinguished Young Scholars Science Fund of the Natural Science Foundation of Hebei Province
- Technology Project of Hebei Education Department
- the central government guides to local funds for science and technology development for Hebei Province
- S and T Program of Hebei
- The Key Laboratory of Neural and Vascular Biology, Ministry of Education
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Jiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024). Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases. Pharmaceutics, 16(12), 1611. https://doi.org/10.3390/pharmaceutics16121611
Vancouver
Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J, et al. Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases. Pharmaceutics. 2024;16(12):1611. doi:10.3390/pharmaceutics16121611
BibTeX
@article{Jiao2024,
author = {Jiao, Yimai and Yang, Luosen and Wang, Rujuan and Song, Guoqiang and Fu, Jingxuan and Wang, Jinping and Gao, Na and Wang, Hui},
title = {Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1611},
doi = {10.3390/pharmaceutics16121611}
}
EUVIMED